Literature DB >> 9624555

Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate.

T Goto1, S Makinose, Y Ohi, D Yamauchi, T Kayajima, K Nagayama, H Hayami.   

Abstract

BACKGROUND: The successful treatment of bacterial prostatitis depends on an effective antimicrobial concentration in prostatic tissue against the infecting organism. In this study we compared the diffusion of 5 types of antimicrobials into the prostate.
METHODS: The concentrations of piperacillin, cefotiam, minocycline, amikacin, and ofloxacin were determined in prostatic fluid, prostatic tissue, and serum 2.5 to 3 hours after a single administration from 55 patients with benign prostatic hypertrophy.
RESULTS: Although amikacin showed the highest mean concentration both in prostatic tissue and prostatic fluid, the prostatic tissue/serum ratio was significantly higher (P < 0.01) for ofloxacin (1.49 +/- 0.80) and minocycline (0.94 +/- 0.39) compared with those for amikacin (0.49 +/- 0.21) and piperacillin (0.21 +/- 0.15). Also, the prostatic fluid/serum ratio was lower than the prostatic tissue/serum ratio for each drug, however, the prostatic fluid/serum ratio of ofloxacin was significantly higher than that of other antimicrobials tested (P < 0.01).
CONCLUSION: These results support earlier studies demonstrating that fluoroquinolones are a useful class of antimicrobials for the treatment of chronic bacterial prostatitis. They also suggest that in view of the pharmacokinetic properties and antimicrobial activities, amikacin and minocycline may be alternate antimicrobial options for selected patients with bacterial infections of the prostate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624555     DOI: 10.1111/j.1442-2042.1998.tb00597.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  12 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  [Infection and sepsis prevention in prostate biopsy].

Authors:  F M E Wagenlehner; A Pilatz; P Waliszewski; T Dansranjavin; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

Review 3.  Reducing infection rates after prostate biopsy.

Authors:  Florian M E Wagenlehner; Adrian Pilatz; Przemyslaw Waliszewski; Wolfgang Weidner; Truls E Bjerklund Johansen
Journal:  Nat Rev Urol       Date:  2014-01-14       Impact factor: 14.432

4.  Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review.

Authors:  Jordon T Walker; Nirmish Singla; Claus G Roehrborn
Journal:  Rev Urol       Date:  2016

Review 5.  The etiology and management of acute prostatitis.

Authors:  Christopher M Brede; Daniel A Shoskes
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

Review 6.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

7.  Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.

Authors:  Zhi-Chao Zhang; Feng-Shuo Jin; Dong-Ming Liu; Zhou-Jun Shen; Ying-Hao Sun; Ying-Lu Guo
Journal:  Asian J Androl       Date:  2012-08-06       Impact factor: 3.285

8.  Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?

Authors:  G Gopal Rao; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2013-08-10       Impact factor: 2.370

Review 9.  Treatment response to conventional and novel therapies in chronic prostatitis.

Authors:  Daniel A Shoskes
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

10.  Prevalence of and Risk Factors for Levofloxacin-Resistant E. coli Isolated from Outpatients with Urinary Tract Infection.

Authors:  Woo Hyuk Jang; Dong Hoon Yoo; Seong Woon Park
Journal:  Korean J Urol       Date:  2011-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.